🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

QuidelOrtho Corporation QDEL R2K

Healthcare · Medical Devices · United States
https://www.quidelortho.com

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

READ MORE ›
$13.02
-57.55% 1Y

Market & Price

Market Cap
$887.85M
Current Price
$13.02
High / Low (52W)
$35.38 / $9.96
Beta
0.74

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
5.33
PEG Ratio
2.06
Book Value
$27.19
Price to Book
0.48
P/S
0.33
EV/EBITDA
7.37
Dividend Yield
-

Profitability & Returns

ROCE
-19.25%
ROE
-49.95%
ROA
0.51%
Profit Margin
-45.57%
Op Margin
-4.10%
EPS (Latest Qtr)
$-1.35
EPS (TTM)
$-17.85

Balance Sheet & Liquidity

Debt/Equity
1.55
Quick Ratio
0.65
Current Ratio
1.43
Debt
$2.87B
Total Assets
$5.77B
Current Assets
$1.45B
Working Capital
$481.20M

Ownership

Promoter Holding
0.84%
Chg in Prom Hold
0.00%
FII / Inst Holding
124.06%
Chg in FII Hold
0.09%

Financial Snapshot

Enterprise Value
$3.62B
Total Revenue (TTM)
$2.66B
EBITDA
$491.70M
Free Cash Flow
$208.58M
Operating Cash Flow
$6.60M
Shares Outstanding
68.19M
Gross Margin
45.18%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
-5.80%
Profit 5Y
-102.09%
Revenue (YoY)
-10.50%
Earnings (YoY)
-

PROS

  • Generates positive free cash flow.

CONS

  • Revenue declined at -5.8% CAGR over 5 years.
  • Earnings shrank at -102.1% CAGR over 5 years.
  • Trading 63.2% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 QDEL QuidelOrtho Corporation R2K 13.02 - $887.85M - -19.25% -49.95% -5.80% -102.09%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Apr 2021Jul 2021Oct 2021Apr 2022Jul 2022Oct 2022Apr 2023Jul 2023Oct 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -176.60M509.80M1.00B613.40M783.80M846.10M665.10M744.00M711.00M637.00M--692.80M613.90M699.90M723.60M619.80M
Cost of Revenue -------------349.50M339.00M364.30M403.20M356.00M
Gross Profit -------------343.30M274.90M335.60M320.40M263.80M
Operating Expenses -------------294.60M276.70M290.40M357.70M291.20M
Operating Income -23.30M281.80M620.70M79.70M56.80M99.60M-26.90M26.30M-1.76B-117.50M--48.70M-1.80M45.20M-37.30M-27.40M
EBITDA -------------140.60M-76.40M-597.00M50.20M81.40M
Interest Expense -------------42.30M42.90M47.80M50.10M48.00M
Pretax Income --------------8.80M-229.60M-756.90M-112.40M-79.50M
Tax Provision -------------3.90M25.80M-23.90M18.30M12.30M
Net Income 178.10M19.10M215.70M479.90M19.30M19.20M48.80M-53.20M-12.70M-1.71B-147.70M---12.70M-255.40M-733.00M-130.70M-91.80M
Diluted EPS -0.455.0811.310.360.280.73-0.80-0.19-25.50-2.20---0.19-3.77-10.78-1.92-1.35
R&D Expense -22.60M23.70M26.40M34.20M65.60M62.30M62.40M61.50M59.20M56.30M55.90M-53.20M45.70M41.50M-44.90M

Profit & Loss (Annual)

Figures in USD.

Metric Jan 2021Dec 2021Jan 2022Dec 2022Jan 2023Dec 2023Dec 2024Dec 2025
Revenue 1.66B-1.70B3.27B3.27B3.00B2.78B2.73B
Cost of Revenue ---1.33B-1.50B1.50B1.46B
Gross Profit ---1.94B-1.50B1.29B1.27B
Operating Expenses ---953.70M-1.24B1.24B1.22B
Operating Income 1.06B-906.00M982.50M843.70M257.00M45.80M54.80M
EBITDA ---1.09B-607.00M-1.49B-482.60M
Interest Expense ---74.50M-178.90M188.30M183.10M
Pretax Income ---735.90M--29.10M-2.13B-1.11B
Tax Provision ---187.20M--19.00M-79.50M24.10M
Net Income 810.30M-704.20M548.70M548.70M-10.10M-2.05B-1.13B
Diluted EPS 18.6016.4316.439.569.56-0.15-30.16-
R&D Expense 84.30M-95.70M-187.90M245.00M218.70M186.20M

Compounded Sales Growth

5 Years:-5.80%
1 Year:-10.50%

Compounded Profit Growth

5 Years:-102.09%
1 Year:-

Stock Price Performance

1 Year:-57.55%
6 Months:-53.73%
3 Months:-42.74%
1 Month:+13.32%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2019Jan 2021Dec 2021Jan 2022Dec 2022Jan 2023Dec 2023Dec 2024Dec 2025
Total Assets ---2.43B8.86B8.86B8.56B6.42B5.77B
Current Assets ----1.58B-1.31B1.22B1.45B
Cash & Equivalents ---802.80M292.90M292.90M118.90M98.30M169.80M
Inventory ----524.10M-577.80M533.70M577.60M
Receivables ----453.90M-303.30M282.40M417.00M
Total Liabilities ---501.00M3.92B3.92B3.56B3.44B3.85B
Current Liabilities ---323.50M1.01B1.01B833.80M998.80M966.10M
Long Term Debt ----2.43B2.65B2.27B2.14B2.47B
Total Debt ----2.85B-2.61B2.68B2.83B
Total Equity 559.90M1.33B-1.93B4.93B4.93B5.01B2.98B1.92B
Shares Outstanding ----66.40M-66.70M67.26M67.93M

Cash Flows (Annual)

Figures in USD.

Metric Jan 2021Dec 2021Jan 2022Dec 2022Jan 2023Dec 2023Dec 2024Dec 2025
Operating Cash Flow 629.70M-805.90M885.30M885.30M280.20M83.00M105.20M
Investing Cash Flow -63.30M--319.50M-1.64B-1.64B-187.60M-149.90M-192.70M
Financing Cash Flow -130.30M--173.10M252.00M252.00M-265.80M48.80M155.80M
Capital Expenditure -64.90M--292.80M-140.90M-140.90M-209.30M-195.10M-188.20M
Free Cash Flow 564.80M-513.10M744.40M744.40M70.90M-112.10M-83.00M
Net Change in Cash ----506.90M--173.20M-18.10M68.30M
Share Buybacks 43.70M-103.50M-74.30M7.20M00

Ratios (Annual)

Figures in %.

Metric Jan 2021Dec 2021Jan 2022Dec 2022Jan 2023Dec 2023Dec 2024Dec 2025
Gross Margin % ---59.3%-49.9%46.2%46.7%
Operating Margin % 63.8%-53.3%30.1%25.8%8.6%1.6%2.0%
Net Margin % 48.8%-41.5%16.8%16.8%-0.3%-73.7%-41.5%
ROE % 60.8%-36.5%11.1%11.1%-0.2%-68.8%-58.9%
ROCE % --43.0%12.5%10.7%3.3%0.8%1.1%

Shareholding Pattern

Insiders
0.84%
Institutions
124.06%
Public Float
125.11%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 15.32% 10.45M $136.05M
2 FMR, LLC 9.67% 6.59M $85.82M
3 T. Rowe Price Investment Management, Inc. 8.26% 5.63M $73.30M
4 Newtyn Management, Llc 6.68% 4.56M $59.35M
5 Vanguard Portfolio Management LLC 5.91% 4.03M $52.49M
6 Rubric Capital Management LP 4.85% 3.31M $43.05M
7 Invesco Ltd. 4.57% 3.12M $40.59M
8 Vanguard Capital Management LLC 4.48% 3.05M $39.75M
9 Dimensional Fund Advisors LP 4.47% 3.05M $39.69M
10 American Century Companies Inc 4.19% 2.86M $37.19M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for QDEL

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks